



DT05 Rec'd PCT/PTO 19 AUG 2002 *receipt*

427.057

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
CHABRIER DE LASSAUNIERE et al :
Serial No.: 10/089,993 : Group: 1615
Filed: April 4, 2002 :
For: DERIVATIVES...AS MEDICAMENTS :

600 Third Avenue
New York N.Y. 10016
July 15, 2002

RECEIVED
SEP 25 2002
TCH CENTER 1600/290

REQUEST FOR CORRECTED FILING RECEIPT

Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants are returning herewith the filing receipt for the above application and it is requested that the Patent Office issue a new filing receipt to show that the first name of the fourth inventor is JACQUES and not Jacuques.

Respectfully submitted,
Bierman, Muserlian and Lucas

By:

Charles A. Muserlian
Charles A. Muserlian #19,683
Attorney for Applicants
Tel.# (212) 661-8000

CAM:ds
Enclosures

EV 068844274 US
Aug 19, 2002
Aug 19, 2002
D. Rakonicej

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/089,993	04/04/2002	1615	890	427.057		20	3

CONFIRMATION NO. 5815

20311
BIERMAN MUSERLIAN AND LUCAS
600 THIRD AVENUE
NEW YORK, NY 10016

RECEIVED
JUL - 5 2002

FILING RECEIPT



OC000000008379287

Date Mailed: 07/01/2002

BIERMAN, MUSERLIAN AND LUCAS

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Pierre Etienne Chabrier de Lassauniere, Paris, FRANCE;
Jeremiah Harnett, Gif-Sur-Yvette, FRANCE;
Denis Bigg, Gif-Sur-Yvette, FRANCE;
Jacques Pommier, Paris, FRANCE;
Jacques Lannoy, Bievres, FRANCE;
Anne-Marie Liberatore, Auffargis, FRANCE;
Christophe Thurieau, Paris, FRANCE;

RECEIVED
SEP 25 2002
TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/FR00/02805 10/10/2000

Foreign Applications

FRANCE 99 12643 10/11/1999
FRANCE 00 10151 08/01/2000
FRANCE 00 11169 09/01/2000

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No



5-Membered heterocycle derivatives, production thereof and use thereof as medicaments

Preliminary Class

514

RECEIVED

SEP 20 2002

TECH CENTER 1600/2900

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).